Scientists at Skoltech and MSU have investigated the antibiotic nibomycin, which has proven to be effective against bacteria that are resistant to other antibiotics.Their study was published in the journal Antibiotics and chemotherapy..
All bacterial cells contain topoisomerases. This is an important group of enzymes that help address the spatial difficulties associated with bacterial cell division associated with circular DNA replication. There are two types of topoisomerases, I and II, depending on the cleavage (single or double) produced by the DNA. Type II often acts as a target for antibiotics, including fluoroquinolones (FQs), a common group of antibiotics, including levofloxacin and ciprofloxacin. Unfortunately, bacteria easily acquire resistance to FQ through mutations in the gene encoding topoisomerase.
The emergence of resistant pathogens is a global problem in healthcare, so identifying alternative pathways to prevent their persistence is the current frontier in drug discovery. Nibomycin, which has been reported to be a “reverse antibiotic,” can block fluroquinolone-resistant DNA gyrase, a type II topoisomerase. Previously, this effect was only observed with Gram-positive bacteria (bacteria can be either Gram-positive or Gram-negative, depending on the structure of the cell wall).
For the first time, a team led by Skoltech and a professor at Moscow State University, Olga Dontsova, has demonstrated the effects of “reverse antibiotics” on Gram-negative bacteria and that nibomycin is also effective against unstable topoisomerases.
“Interestingly, the first inhibitors of type II topoisomerases were found in the artificially synthesized molecule quinolones. Nowadays, more and more natural molecules are effective against the same target. Nibomycin, a natural inhibitor of topoisomerase II, destroys fluoroquinolone-resistant gyrases, which means that the classic gyrase inhibitor, fluoroquinolones, can be used if it does not work. This is the first study to investigate the details of inhibition of topoisomerase II in gram-negative bacteria using nibomycin, which has been shown to block fluoroquinolone-sensitive and fluoroquinone-resistant gyrases in Escherichia coli. Described in the Center for Life Sciences.
According to Olga Dontsova, “finding a way to overcome bacterial resistance to antibiotics is especially important in pandemics of frequent secondary bacterial infections that are difficult to fight.”
success! You are on the list.
Oops! An error occurred and the subscription could not be processed. Please reload the page and try again.
“Reverse antibiotics” may be new antibiotics. – Science Inquirer
https://scientificinquirer.com/2021/03/06/reverse-antibiotics-may-be-the-new-antibiotics/ “Reverse antibiotics” may be new antibiotics. – Science Inquirer